Patient's Query
Hi doctor,
I am a 36-year-old female diagnosed with neuromyelitis optica spectrum disorder (NMOSD) four years ago, confirmed with positive aquaporin-4 antibody. I have had two major relapses in the past year, with optic neuritis and transverse myelitis, leaving me with persistent weakness in both legs.
My latest MRI spine showed multiple lesions in the cervical and thoracic cord. Along with NMOSD, I also have systemic lupus erythematosus (SLE), diagnosed six years ago. My recent ANA was positive with a titer of 1:640, dsDNA was 120 IU/mL, and complement C3 was low at 62 mg/dL. My hemoglobin is 9.8 g/dL, indicating anemia, and ESR was 64 mm/hr.
I am currently on Rituximab infusion every six months, Hydroxychloroquine 200 mg daily, and low-dose steroids. My blood pressure averages around 142/88 mmHg, and I often experience fatigue and joint pains along with my neurological problems.
I am worried about frequent relapses, the impact of overlapping autoimmune diseases, and whether my current medications are enough to control both NMOSD and lupus. Can you please explain how NMOSD and SLE are connected, and what treatment strategies might reduce my relapse risk while protecting my overall health?
Please advise.
Hi,
Welcome to icliniq.com
Neuromyelitis optica spectrum disorder (NMOSD) and systemic lupus erythematosus are both autoimmune diseases, and while they are distinct conditions, they can overlap in the same person because of a shared tendency for the immune system to attack the body’s own tissues.
In your case, the presence of aquaporin-4 antibodies confirms NMOSD, which primarily targets the optic nerves and spinal cord, while lupus involves widespread immune dysregulation affecting joints, blood, kidneys, and other organs. This overlap makes management more complex because both conditions can cause inflammation, anemia, fatigue, and neurological complications.
Rituximab is a very appropriate treatment, as it targets B cells that drive both NMOSD relapses and lupus activity, and studies show it can reduce relapse rates in NMOSD significantly. Hydroxychloroquine is helpful for lupus joint and systemic symptoms, while low-dose steroids are often used to keep disease activity under control, though minimizing steroid exposure long-term is important to reduce side effects.
Despite these treatments, your frequent relapses suggest that disease activity is still high, so your doctors may consider closer monitoring of B-cell counts to optimize Rituximab timing or switching to another NMOSD therapy such as Eculizumab, Inebilizumab, or Satralizumab, which specifically target immune pathways involved in NMOSD relapses.
For lupus, monitoring double-stranded deoxyribonucleic acid (dsDNA), complement levels, and blood counts will help guide whether additional immunosuppressants are needed. Addressing anemia, blood pressure, and fatigue is also essential, since chronic inflammation and medications can worsen cardiovascular risk and quality of life.
A coordinated approach between your neurologist and rheumatologist is the best way forward, ensuring that treatment controls both conditions while protecting long-term health and minimizing complications.
I hope this answers your query.
Thank you.
Was this conversation helpful?
Answered byDr. Ashraf Ghani
Medically reviewed byiCliniq medical review team
Same symptoms don't mean you have the same problem. Consult a doctor now!
Disclaimer: No content published on this website is intended to be a substitute for professional medical diagnosis, advice or treatment by a trained physician. Seek advice from your physician or other qualified healthcare providers with questions you may have regarding your symptoms and medical condition for a complete medical diagnosis. Do not delay or disregard seeking professional medical advice because of something you have read on this website. Read our Editorial Process to know how we create content for health articles and queries.